|
THE FEMALE HEALTH COMPANY REPORTS: Female
Health Company Elects Directors The Female Health Company held its Annual Meeting in Chicago CHICAGO, May
10, 2000-- The Female Health Company (OTC BB:FHCO)
announced today the election of the company’s directors by
shareholders at its annual meeting in Chicago on May 5, 2000.
Directors elected to serve until the 2001 Annual Meeting of
Shareholders include: William R. Gargiulo, Jr., Mary Ann Leeper, Ph.D.,
O.B. Parrish, Stephen M. Dearholt, David R. Bethune, Michael R. Walton
and James R. Kerber. No
Director received a vote of less than 88 percent of the outstanding
shares. In addition, 85 percent of the outstanding shares
voted to increase the number of shares of common stock authorized by 5
million shares bringing the total number of common stock authorized up
from 22 million to 27 million shares.
Potential uses, as noted in the proxy,
include possible issuance to investors in Japan and for financial
and other general corporate purposes.
The shareholders also ratified the appointment of McGladrey &
Pullen LLP as the Company’s independent auditors. Highlights of the meeting included a review of
the launch of the Female Condom (Myfemy) in Japan, which occurred on April
24, 2000. The launch was well
executed and the initial response quite positive.
Promotional materials from the launch of the Female Condom in Japan
and Japanese product packages were available for inspection by
shareholders. In addition, a program guide titled “The
Female Condom: A Guide for Planning and Programming” for use in
implementing female condom programs in developing countries was
introduced for the first time. Based
on real experience, the guide was developed in conjunction with the World
Health Organization (WHO) and the Joint United Nations Program on HIV/AIDS
(UNAIDS). The guide
emphasizes the importance of the female condom, outlines strategic steps
to introduce and integrate it into reproductive health programs and
underscores the worldwide support of the female condom on behalf of WHO
and UNAIDS. The guide will be
featured at the Durban 2000 International AIDS Conference this July in
South Africa and used to accelerate the availability of the female condom
in developing countries. The Female Health Company, based in Chicago, owns certain worldwide rights to the Female Condom including patents which have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, The People’s Republic of China, Canada, New Zealand, South Korea and Australia. The Female Condom is the only available product controlled by a woman that protects against sexually transmitted diseases including HIV/AIDS and unintended pregnancy. “Safe
Harbor” Statement under the Private Securities Litigation Reform Action
of 1995: The statements in this release which are not historical fact are
forward-looking statements based upon the Company’s current plans and
strategies, and reflect the Company’s current assessment of the risks
and uncertainties related to its business, including such things as
product demand and market acceptance; the economic and business
environment and the impact of governmental regulations, both in the United
States and abroad; the effects of competitive products and pricing
pressures; currency risks; capacity; efficiency and supply constraints;
and other risks detailed in the Company’s press releases, shareholder
communication and Securities and Exchange Commission filings.
Actual events affecting the
Company and the impact of such events on the Company’s operations may
vary from those currently anticipated. For more
information about the Female Health Company, dial toll-free via fax, ### William R. Gargiulo, Jr. Mary Ann Leeper,Ph.D. Desta Davis 231.526.1244 312.280.1119 312.397.6070 If you have any questions or comments, please send them to us info@femalehealth.com |
